Detailansicht
Ageing and Dementia
Current and Future Concepts, Journal of Neural Transmission. Supplementa 62
ISBN/EAN: 9783211837962
Umbreit-Nr.: 5967743
Sprache:
Englisch
Umfang: viii, 384 S.
Format in cm:
Einband:
kartoniertes Buch
Erschienen am 20.08.2002
Auflage: 1/2002
- Zusatztext
- InhaltsangabeContents Jellinger, K. A.: Vascular-ischernic dementia: an Update. l van Dijk, E. J., Prins, N. D., Vermeer, S. E., Koudstaal, P. J., Breteler, M. M. B.: Frequency of white matter lesions and silent lacunar infarets.25 Kapeller, P., Schmidt, R., Enzmger, Ch., Ropele, S., Fazekas, F.: CT and MRI rating of white matter changes.41 Schmidt, R., Fazekas, F., Enzinger, C., Ropele, S., Kapeller, P., Schmidt, H.: Risk factors and progression of small vessel disease-related cerebral abnormalities.47 Schmidt, H., Fazekas, F., Schmidt, R.: Microangiopathy-related cerebral damage and angiotensinogen gene: from epidemiology to biology. 53 Fazekas, F., Ropele, S., Schmidt, R.: Can small-vessel disease-related cerebral abnormalities be used as a Surrogate marker for vascular dementia trials?.61 Perry, G., Nimomura, A., Cash, A. D., Taddeo, M. A., Hirai, K., Aliev, G, Avila, J., Wataya, T., Shimohama, S., Atwood, C. S., Smith, M. A.: Reactive oxygen: its sources and significance in Alzheimer disease. 69 Arendt T.: Dysregulation of neuronal differentiation and cell cycle control in Alzheimer's disease.77 Kienzl, E., Jellinger, K., Janetzky, B., Steindl, H., Bergmann, J.: A broader horizon of Alzheimer pathogenesis: ALZAS - an early serum biomarker?.87 Smith, G.: ls mild cognitive impairment bridging the gap between normal aging and Alzheimer's disease?. 97 Fischer, P., Jungwirth, S., Krampla, W., Weissgram, S., Kirchmevr, W., Schreiber, W., Huber, K., Rainer, M., Tragl, K. H.: Vienna-Transdanube-Aging "VITA": study design, recruitment strategies and level of participation.105 Airnkvist, 0., Axelman, K., Basun, H., Wahlund, L.-O., Lannfelt, L.: Conversion from preclinical to clinical stage of Alzheimer's disease as shown by decline of cognitive function in carriers of the Swedish APP-mutation.117 Kurz, A., Riemenschneider, M., Drzezga, A., Lautenschlager, N.: The role of biological markers in the early and differential diagnosis of Alzheimer's disease.127 Schmitt, F. A., Cragar, D., Ashford, J. W., Reisberg, B., Ferris, S., Möbius, H.-J., Stöffler, A.: Measuring cognition in advanced Alzheimer's disease for clinical trials. 135 Windisch, M., Hutter-Paier, B., Schreiner, E.: Current drugs and future hopes in the treatment of Alzheimer's disease. 149 FloresFlores, C., Nissirn, A., Shochat, S., Soreq, H.: Development of human anti body fragments directed towards synaptic acetylcholinesterase using a semi- synthetic phase display library. 165 Giacobini, E.: Long-term stabilizing effect of cholinesterase inhibitors in the therapy of Alzheimer' disease.